Stocks and Investing
Stocks and Investing
Thu, December 9, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Jay Olson Maintained (ACAD) at Hold with Increased Target to $23 on, Dec 9th, 2021
Jay Olson of Oppenheimer, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Increased Target from $20 to $23 on, Dec 9th, 2021.
Jay has made no other calls on ACAD in the last 4 months.
There are 5 other peers that have a rating on ACAD. Out of the 5 peers that are also analyzing ACAD, 4 agree with Jay's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Salveen Richter of "Goldman Sachs" Maintained at Hold with Increased Target to $28 on, Wednesday, December 8th, 2021
- Vamil Divan of "Mizuho" Maintained at Hold with Increased Target to $26 on, Tuesday, December 7th, 2021
- Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Increased Target to $24 on, Tuesday, December 7th, 2021
- Neena Bitritto-Garg of "Citigroup" Maintained at Hold with Increased Target to $28 on, Tuesday, December 7th, 2021
This is the rating of the analyst that currently disagrees with Jay
- Yatin Suneja of "Guggenheim" Upgraded from Hold to Strong Buy and Held Target at $23 on, Monday, November 1st, 2021
Contributing Sources